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The cause of thymoma, a rare malignancy of thymic epithelial cells, is unknown. Recent studies have reported the detection of DNA
from human T-cell lymphotropic virus type I (HTLV-I) and human foamy virus (HFV) in small numbers of thymoma tumours,
suggesting an aetiologic role for these retroviruses. In the present study, we evaluated 21 US thymoma patients and 20 patients with
other cancers for evidence of infection with these viruses. We used the polymerase chain reaction to attempt to amplify viral DNA
from tumour tissues, using primers from the pol and tax (HTLV-I) and gag and bel1 (HFV) regions. In these experiments, we did not
detect HTLV-I or HFV DNA sequences in any thymoma or control tissues, despite adequate sensitivity of our assays (one HTLV-I
copy per 25000 cells, one HFV copy per 7500 cells). Additionally, none of 14 thymoma patients evaluated serologically for HTLV I/II
infection was positive by enzyme-linked immunoassay (ELISA), while five (36%) had indeterminate Western blot reactivity. In
comparison, one of 20 US blood donors was HTLV-I/II ELISA positive, and nine (45%) donors, including the ELISA-positive donor,
had indeterminate Western blot reactivity. Western blot patterns varied across individuals and consisted mostly of weak reactivity. In
conclusion, we did not find evidence for the presence of HTLV-I or HFV in US thymoma patients.
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Thymoma is a rare malignancy of thymic epithelial cells of
unknown aetiology. Thymoma usually arises in middle-aged or
elderly adults (Engels and Pfeiffer, 2003). The tumour is closely
associated with several autoimmune conditions, especially
myasthenia gravis (Thomas et al, 1999). Patients with thymoma
are at increased risk of developing non-Hodgkin’s lymphoma and
perhaps other malignancies (Masaoka et al, 1994; Welsh et al,
2000; Engels and Pfeiffer, 2003).
Of interest, recent reports have suggested that two retroviruses
could play a causal role in thymoma. DNA sequences from human
T-cell lymphotropic virus type I (HTLV-I), the viral cause of adult
T-cell leukaemia/lymphoma, were detected in tumour tissue
obtained from 11 Italian thymoma patients (Manca et al, 2002).
Notably, HTLV-I infection is rare in Italy, and none of the patients
had obvious risk factors for infection. The other retrovirus
possibly implicated in thymoma is human foamy virus (HFV),
originally isolated from an African patient with nasopharyngeal
carcinoma. Despite its name, HFV is not clearly a natural infection
of humans (Meiering and Linial, 2001). Nonetheless, Saib et al
(1994) identified HFV DNA sequences in peripheral blood
mononuclear cells from a myasthenia gravis patient from the
Indian Ocean island of Comoros. Subsequently, Liu et al (1996)
amplified HFV DNA sequences from thymus tissue obtained from
four Taiwanese patients with myasthenia gravis, two of whom had
thymoma.
In the present US-based investigation, we sought to confirm the
previously reported detection of these two retroviruses, HTLV-I
and HFV, in thymoma tumours. We also evaluated patient sera for
HTLV-I and HTLV-II antibodies.
MATERIALS AND METHODS
Patients
The study included archived tumour samples (stored at or below
 701C) from 21 thymoma patients treated at the Indiana
University Cancer Center. Clinical data were unavailable for one
patient. For the remainder, 10 were female, and the median age at
thymoma diagnosis was 48 years (range 22–76). A total of 18
(90%) were white, two were black (10%), and all were born in and
resided in the US. By World Health Organization histologic
classification (Dadmanesh et al, 2001), subjects had subtypes A
(n¼1), B1 (n¼9), B2 (n¼6), B3 (n¼3), and C (n¼1). By
Masaoka stage (Masaoka et al, 1981), subjects had tumours of
stage I (n¼5), II (n¼8), III (n¼2), IVa (n¼4), and IVb (n¼1).
Four patients (20%) had myasthenia gravis, while five patients
(25%) had a history of or developed additional cancers during
clinical follow-up (one case each of prostate cancer, non-small-cell
lung cancer, thyroid cancer, ovarian cancer, and glioblastoma).
Serum samples were available for 14 of these 21 patients.
For control tissues, we evaluated archived tumour samples
(stored at  701C) from US patients with colon cancer (five cases),
breast cancer (seven), or lung cancer (eight). For antibody studies,
we used sera from 20 US blood donors as controls. All specimens
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information.
Molecular detection of HTLV-I and HFV
DNA extraction and polymerase chain reaction (PCR) experiments
were performed simultaneously for thymoma cases and controls.
DNA was extracted from tissues using the DNeasy Tissue Kit
(QIAGEN, Valencia, CA, USA) according to the manufacturer’s
instructions. Briefly, for each specimen, 15–20mg of minced tissue
was lysed overnight in Tissue Lysis Buffer and 20ml proteinase K
solution (20mgml
 1)a t5 5 1C. Subsequently, 4ml of RNase A
solution (100mgml
 1) was added and incubated at 371C for
10min. The mixture was then placed on a QIAamp spin column.
DNA was eluted after two wash steps, and spectrophotometry was
used to quantify DNA and assess its purity. DNA yield was similar
for thymoma tissues and control specimens (median 34mg, range
3–212 from thymoma specimens, vs median 27mg, range 12–61
from control specimens; P¼0.51). Extracted DNA was of high
purity (median OD260/OD280 ratio 1.86, range 1.72–1.99 for
thymoma specimens; median 1.83, range 1.76–1.89 for control
specimens).
For PCR detection of HTLV-I and HFV, we used primers from
the pol and tax (HTLV-I) and gag and bel1 (HFV) regions.
Specifically, HTLV-I sequences were amplified using SG231/SG238
for pol (239bp product, nucleotide position 2802–3038) (Ehrlich
et al, 1990) and SK43/SK44 for tax (161bp product, nucleotide
position 7359–7517) (Saito and Ichijo, 1992; Manca et al, 2002).
Human foamy virus sequences were amplified using NC#8/PR#2
for gag (504bp product, nucleotide position 3354–3855) (Yu et al,
1999) and #50bel1/#30bel1 for bel1 (704bp product, nucleotide
position 10182–10883) (Yu et al, 1996). In each PCR experiment,
500ng DNA was used as template in a 50ml reaction volume
containing 1  PCR buffer (Perkin-Elmer, Branchburg, NJ, USA),
1.5mM MgCl2, 250mM of each dNTP (Gibco/BRL, Grand Island,
NY, USA), 2.5U of AmpliTaq Gold polymerase (Roche, Indiana-
polis, IN, USA), and 25pmol of each primer. Polymerase chain
reaction amplification was performed as follows: preheat at 951C
for 10min, 40 cycles of amplification (951C3 0s ,5 8 1C 1min, 721C
30s), followed by a final elongation step at 721C for 10min.
Amplified products were analysed by 2% agarose gel electrophor-
esis with ethidium bromide staining. Positive controls were serial
10-fold dilutions of DNA from the HTLV-I-infected T-cell line
MT1 or HFV plasmid pcHSRV2/2 (gift of Dr O Herchenro ¨der,
Dresden, Germany), calculated to contain 3 10
4–3 10
 1 copies
of HTLV-I DNA or 10
6–10
1 copies of HFV DNA per reaction,
respectively.
Protective clothing, dedicated equipment, newly prepared
reagents and primers, and UV irradiation were used to prevent
PCR contamination. Sample preparation, PCR amplification, and
postamplification processing were performed in separate rooms.
Additionally, to prevent contamination by laboratory controls, all
PCR experiments were performed twice: the first PCR experiments
were performed in the absence of positive controls and titration
series (‘suicide’ PCR) (Raoult et al, 2000), while the second PCR
experiments were subsequently repeated in the presence of
positive controls to confirm the initial results. In a separate
experiment (data not shown), we confirmed that samples
contained adequate amounts of amplifiable human DNA using a
quantitative PCR assay for human endogenous retrovirus 3 (Yuan
et al, 2001).
HTLV serology
Sera were tested for HTLV-I and HTLV-II antibodies by enzyme-
linked immunoassay (ELISA; Dupont, Wilmington, DE, USA) and
Western blot (HTLV Blot 2.4, Genelabs Technologies, Singapore)
according to the manufacturer’s protocol. Western blot bands were
scored on a grey scale from 0 (absent) to 10 (maximum intensity).
For HTLV-I, Western blot reactivity was defined as the presence of
bands (2þ intensity) for recombinant gp46I and gp21 (env
proteins) and p19 and p24 (gag proteins). For HTLV-II, bands of
2þ intensity for recombinant gp46II (env) and p24 (gag) were
considered diagnostic. Weak reactivity (intensity ¼ 1 on the gray
scale) on these bands or reactivity only for other viral proteins was
considered indeterminate for HTLV-I/II infection.
RESULTS
Using DNA extracted from thymomas, PCR amplification experi-
ments for HTLV-I (pol and tax) and HFV (gag and bel1) were all
negative. These experiments were performed twice for each
specimen (once without positive controls, followed by once with
positive controls), with complete concordance. Figure 1 shows
results from experiments with positive controls, using primers
from HTLV-I pol (panel A) and HFV bel1 (panel B). In these
experiments, serial dilutions of the positive control DNA demon-
strated that PCR could identify three HTLV-I copies and 10 HFV
copies per reaction (Figure 1).
By ELISA, 14 of 14 thymoma patients and 19 of 20 blood donor
controls were HTLV-I/II seronegative, while one blood donor
(BD15) was HTLV-I/II seropositive. By Western blot, none of the
35 evaluated subjects was HTLV-I or HTLV-II seropositive.
Indeterminate Western blots were observed in five thymoma
patients (36%) and nine blood donors (45%); in most of these
subjects, reactivity was weak (Figure 2). Among thymoma patients
with indeterminate Western blots, two had reactivity to env but not
gag, and three had reactivity to gag but not env. Among blood
donors, five had reactivity to env but not gag, and one had
reactivity to gag but not env. Two blood donors (BD5 and BD15)
had reactivity to both gag and env (but this reactivity did not meet
our criteria for Western blot positivity), and one donor had
reactivity only to Western blot proteins other than gag and env.
DISCUSSION
HTLV-I and foamy viruses infrequently cause infections in humans
(Schweitzer et al, 1995; Ali et al, 1996; Anonymous, 1996) but can
integrate into and disrupt the host genome, making them
potentially attractive agents for causing rare cancers such as
thymoma. Nonetheless, using samples obtained from US patients,
we were unable to confirm prior reports that either HTLV-I or
HFV DNA is present in thymoma tumour tissue (Saib et al, 1994;
Liu et al, 1996; Manca et al, 2002).
The single prior report of HTLV-I detection in thymoma was
from Italy (Manca et al, 2002). In that study, Manca et al tested
thymic tissue from 27 patients with myasthenia gravis (12 with
thymoma, 15 with thymic hyperplasia). A DNA sequence
corresponding to the HTLV-I regulatory gene tax was amplified
from most cases (92% of thymomas, 93% of thymic hyperplasia
specimens), whereas DNA corresponding to the structural gene pol
was found in fewer tissues (75% of thymomas, 40% of thymic
Figure 1 PCR amplification of HTLV-I and HFV sequences from thymoma and control tumour tissues. (A) Ethidium bromide stained gels of PCR
products corresponding to HTLV-I pol region from a single experiment, obtained using the SG231/SG238 primer set. Gels include lanes for molecular size
markers (MM), a titration series of HTLV-I DNA from MT1 cells (3 10
4–3 10
 1), no-template control (NTC), 20 tumour tissue controls (TC1-TC20),
and 21 thymoma tissues (TT1-TT21). (B) Ethidium bromide stained gels of PCR products corresponding to HFV bel1 region from a single experiment,
obtained using #50bel1/#30bel1 primer set. Gels include lanes for MM, a titration series of HFV plasmid DNA (10
7–10
1 copies), 20 tissue controls (TC1-
TC20), and 21 thymoma tissues (TT1-TT21). Arrows show the size of amplified products (239bp for HTLV-I pol, 704bp for HFV bell).
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yhyperplasia specimens). Additionally, sera from 83 other myasthe-
nia gravis patients were studied by the same group (Manca et al,
2002). All were negative for HTLV-I/II antibodies by ELISA. A total
of 17 sera were evaluated further by Western blot, and all showed
antibody reactivity against recombinant HTLV-I/II p21 envelope
protein, consistent with an indeterminate HTLV-I serology (only
two showed reactivity against the gag protein p19).
The reasons why our findings regarding HTLV-I, which were
convincingly negative, differ from those of Manca et al are unclear.
Although a limitation of our study was its small size and the
selection of patients from a single referral institution, our study
included thymoma patients from various demographic categories
and tumour subtypes. We amplified the same two HTLV-I gene
regions as Manca et al did, and one primer set (SK43/SK44) was
the same in both studies. In our experiments, we would have
detected as few as three HTLV-I pol or tax copies in 500ng
genomic DNA, equivalent to one copy per 25000 cells, had the
virus been present. Thus, our assays were sufficiently sensitive to
rule out the presence of HTLV-I in these specimens.
Similarly, we did not find evidence for a specific HTLV-I or
HTLV-II antibody pattern in thymoma patients. One blood donor
control had a positive ELISA result and indeterminate Western
blot, suggesting that he might have been exposed to or infected
with HTLV-I or HTLV-II. All other subjects were ELISA negative,
and overall, equivalent proportions of thymoma patients and
blood donor controls manifested indeterminate Western blots. In
our study, p21 seroreactivity was weak and observed in only one
thymoma patient (7%, in contrast to Manca et al) and four blood
donors (20%). The limited-spectrum and mostly weak-intensity
Western blot reactivity, coupled with the negative ELISA results,
indicates that thymoma patients were infected with neither HTLV-
I nor HTLV-II.
Furthermore, there is little epidemiological evidence to relate
thymoma to HTLV-I infection. HTLV-I is endemic in some areas of
Japan, and interestingly, thymoma is more frequently diagnosed in
the US among Asians/Pacific Islanders than in other racial groups
(Engels and Pfeiffer, 2003). However, the excess of thymoma in the
US is not limited to Japanese (National Cancer Institute Surveil-
lance, Epidemiology, and End Results data, authors’ unpublished
analyses), and the heightened thymoma incidence in Asians/Pacific
Islanders might be due to other genetic or environmental factors.
We considered the possibility that we missed HTLV-I in thymoma
because HTLV-I infection is uncommon in the US (Anonymous,
1996). Nonetheless, HTLV-I is equally rare in Italy (Anonymous,
1996), and none of the cases studied by Manca et al (2002) had
recognizable risk factors for acquiring HTLV-I.
Foamy viruses infect many mammal species, but no foamy virus
uniquely infecting humans has been identified (Meiering and
Linial, 2001). Based on extensive nucleotide and amino-acid
homology (Herchenro ¨der et al, 1994), the foamy virus originally
isolated from a human (ie, ‘human foamy virus’) may actually be
identical to a chimpanzee simian foamy virus isolate (SFVcpz).
Indeed, the African patient from whom HFV was first isolated
could have acquired the virus from a primate (Meiering and Linial,
2001), since such transmission of SFV can occur through close
animal contact (Schweitzer et al, 1997; Heneine et al, 1998;
Sandstrom et al, 2000; Brooks et al, 2002). Alternatively, the initial
report may have represented a laboratory contamination (Meiering
and Linial, 2001). Two large serosurveys subsequently failed to
find HFV infection in diverse human populations (Schweitzer et al,
Figure 2 HTLV-I/II Western blot results. Results are shown for the nine blood donors (BD) and five thymoma patients (TT) with indeterminate Western
blot results. Columns on the left correspond to positive controls for HTLV-I and HTLV-II and a negative control (NEG). Bands are indicated to the left of the
figure and include a positive serum control (serum), recombinant gp46I and gp46II (rgp46I and rgp46II), and p21 (GD21). Bands were scored 0–10 on a
grey scale (see Materials and Methods); bands scoring 1–2 on this scale are faint and may not be visible in this photograph. For instance, Western blot
reactivity was noted for subject BD15 for bands rgp46I (grey scale level 1), rgp46II (1), p24 (5), p19 (9), and GD21 (1), while for subject TT13 only faint
reactivity was noted for bands p53 (grey scale level 2) and p24 (1).
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with SFVcpz, some investigators refer to HFV as ‘SFVcpz(hu)’
(Meiering and Linial, 2001). Although evidence for infection with
HFV (or a closely related primate virus) has been reported in
patients with a range of autoimmune or idiopathic diseases,
including Graves’ disease, thyroiditis de Quervain, and multiple
sclerosis, later studies cast doubts on those findings (Meiering and
Linial, 2001). Documented human infection with SFV has not been
linked to disease (Schweitzer et al, 1997; Heneine et al, 1998;
Brooks et al, 2002).
There are sparse data regarding a possible role for HFV in
thymoma or myasthenia gravis. Saib et al (1994) studied eight
patients with myasthenia gravis, only one of whom (a female from
Comoros) had HFV DNA sequences detected by PCR in peripheral
blood mononuclear cells. On sequencing, part of the HFV bel1
gene was deleted, suggesting the presence of a replication-
incompetent variant of the virus. Additionally, serum from the
patient reacted to multiple HFV antigens by Western blot and
immunofluorescence assays. Liu et al (1996) reported amplifying
HFV gag and bel2 sequences from thymus tissue of four Taiwanese
patients with myasthenia gravis (two with ‘lymphoepithelioma’
variants of thymoma/thymic carcinoma, two with thymic hyper-
plasia). All four cases also had low-titer neutralising antibody
against HFV. Attempts in both studies to isolate HFV were
unsuccessful (Saib et al, 1994; Liu et al, 1996). Neither study
provided an explanation for how these individuals might have
become infected with a rare human or primate virus.
Using primers designed to detect HFV sequences, we could not
confirm these prior reports for US thymoma patients. With the
same bel1 primer set used by Saib et al (1994), we ruled out the
presence of HFV DNA at a level of one copy per 7500 cells in
tumour tissue obtained from US patients with thymoma. With
similar sensitivity, we excluded the presence of HFV gag
sequences. Our gag primers should also have been able to amplify
SFVcpz DNA, since the 30 primer (PR#2) perfectly matches the
published SFVcpz gag sequence (Herchenro ¨der et al, 1994), while
the 50 primer (NC#8) matches SFVcpz over its 30 end for 16
contiguous nucleotides.
In conclusion, we did not find evidence for HTLV-I or HFV
infection in US thymoma patients. It would be of further interest to
study the relationship between HTLV-I, thymoma, and myasthenia
gravis in geographic areas where HTLV-I is endemic. Since the
cause of thymoma is unknown, further searches for a viral
aetiology may be warranted.
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